The effect of trihexyphenidyl, an anticholinergic agent, on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease

Cerebral blood flow and oxygen metabolism were studied in six previously untreated patients with Parkinson's disease (PD) before and after anticholinergic treatment using positron emission tomography (PET) and compared with six controls. The PET study and an assessment of the disability and cognitive impairment were performed before and after administration of 6 mg trihexyphenidyl for 5 to 11 weeks. All PD patients showed improvements in motor symptoms after the trihexyphenidyl treatment. Cognitive function did not significantly differ between before and after trihexyphenidyl treatment. However, after trihexyphenidyl treatment, rCBF and rCMRO2 decreased by 15% in the striatum and by 10% in all cortical areas contralateral to predominantly symptomatic limbs, and by 10% in the ipsilateral striatum and all cortical areas, significantly below the values of controls in most cerebral cortices and striatum. These findings suggest that trihexyphenidyl inhibits the cortical cholinergic system and significantly decreases rCBF and rCMRO2 in the cerebral cortices without cognitive impairment in untreated patients with PD.

[1]  R. Kurlan,et al.  Drug-induced alzheimerism. , 1988, Archives of neurology.

[2]  Y. Agid,et al.  Confusion, dementia and anticholinergics in Parkinson's disease. , 1982, Journal of neurology, neurosurgery, and psychiatry.

[3]  J. Christophe,et al.  Stereoselectivity of the enantiomers of trihexyphenidyl and its methiodide at muscarinic receptor subtypes. , 1988, European journal of pharmacology.

[4]  P. Vanhoutte,et al.  Mediation by M3‐muscarinic receptors of both endothelium‐dependent contraction and relaxation to acetylcholine in the aorta of the spontaneously hypertensive rat , 1994, British journal of pharmacology.

[5]  A A Lammertsma,et al.  Correction for the Presence of Intravascular Oxygen-15 in the Steady-State Technique for Measuring Regional Oxygen Extraction Ratio in the Brain: 1. Description of the Method , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  I. Nakano,et al.  Parhnson’s Disease: Neuron Loss in the Nucleus Basah Without Concomitant Alzheimer’s Disease , 2004 .

[7]  R. C. Collins,et al.  Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions , 1983, Brain Research.

[8]  Tetsuya Suhara,et al.  Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography , 1993, Neuroscience Letters.

[9]  J. Wess,et al.  Antagonist binding profiles of five cloned human muscarinic receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[10]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[11]  Elliott Richelson,et al.  Studies on Muscarinic Binding Sites in Human Brain Identified with [3H]Pirenzepine , 1986, Journal of neurochemistry.

[12]  T. Jones,et al.  Regional impairment of cerebral oxidative metabolism in Parkinson's disease. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[13]  A. Levey,et al.  Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. , 1993, Life sciences.

[14]  C D Marsden,et al.  Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease , 1993, Journal of neurochemistry.

[15]  W. Koller.  Disturbance of Recent Memory Function in Parkinsonian Patients on Anticholinergic Therapy , 1984, Cortex.

[16]  M. Hamilton,et al.  Development of a rating scale for primary depressive illness. , 1967, The British journal of social and clinical psychology.

[17]  N. Driesen,et al.  Selective neuroanatornic abnormalities in Down's syndrome and their cognitive correlates , 1995, Neurology.

[18]  Satoshi Takahashi,et al.  Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) , 1998, Journal of the Neurological Sciences.

[19]  M E Phelps,et al.  Validation of tomographic measurement of cerebral blood volume with C-11-labeled carboxyhemoglobin. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  T Jones,et al.  Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease , 1985, Neurology.

[21]  M. Modan,et al.  Effects of anticholinergic drugs on memory in Parkinson's disease. , 1982, Archives of neurology.

[22]  T. Momose,et al.  Positron emission tomography of reversible intellectual impairment induced by long-term anticholinergic therapy , 1995, Journal of the Neurological Sciences.

[23]  Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. , 1991, Journal of neural transmission. Supplementum.